Vertex's VX-661 Has Positive Outlook Despite Futility Finding

Although a study testing a combo of the company's cystic fibrosis drug Kalydeco and the investigational VX-661 in patients with minimal CFTR function was ended due to futility, Vertex is on pace for a 2017 filing of the combo in three other CF subpopulations.

Vertex Pharmaceuticals Inc. revealed that a combination including one of its experimental cystic fibrosis drugs failed to show a significant benefit in one of the most challenging CF subpopulations, but three other Phase III trials of the combo are ongoing with an FDA filing anticipated in late 2017.

The company will terminate the study testing the combination of the firm's first marketed CF drug, Kalydeco (ivacaftor), and the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D